Caprock Group’s Altimmune ALT Stock Holding History

Caprock Group’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,200	Closed	-$29K	–	358
2019 Q4	$29K	Buy	+15,200	New	+$28.1K	0.01%	368

Other funds holding ALT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caprock Group's ALT Position: Q1 2020 in Review

Caprock Group sold out of Altimmune (ALT) in Q1 2020, closing a stake of 15,200 shares — an estimated $29K sold.

Caprock Group first reported a position in ALT in Q4 2019 and held it in 1 quarter. The position peaked at $29K in Q4 2019. 29 funds tracked by Wall St. Rank hold ALT as of Q1 2020.

Caprock Group reported no remaining Altimmune position as of Q1 2020 after selling out during the quarter.
Caprock Group sold 15,200 Altimmune shares in Q1 2020, an estimated $29K.
Caprock Group first reported a position in Altimmune in Q4 2019 and held it in 1 quarter.
Caprock Group's Altimmune position peaked at $29K in Q4 2019.
29 funds tracked by Wall St. Rank held Altimmune as of Q1 2020.

Based on Caprock Group's 13F filing for Q1 2020, filed 28 Apr 2020.